The companies will come together to advance robotic laser technology in cataract surgery; improving precision, reducing patient comfort, and providing faster recovery time. Read on to find out ...
Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed.
Swiss eyecare firm Alcon said on Monday it has agreed to a deal worth a potential $430 million with US counterpart Lensar, ...
Hosted on MSN1mon
Alcon forecasts revenue growth in 2025, ready to cope with tariffs(Reuters) -Alcon forecast sales of between $10.2 and $10.4 billion for 2025, in line with market expectations, after the eye care group reported higher fourth-quarter revenue underpinned by its ...
Investing.com -- Alcon (SIX: ALCC) has received an upgrade to a "buy" rating from BofA Securities in a note dated Tuesday, signaling the beginning of an earnings growth cycle for the Swiss eye care ...
Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed. Aurion will operate as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback